The Unspoken Rules of Non-JUPAS Admission to HKU Medicine: A Year-on-Year Look at the Strategic Battle Over Quotas

The Invisible Hand of Non‑JUPAS Admissions at HKU Medicine: A Year‑by‑Year Look at How Institutional Competition Reshapes JUPAS Quotas

In Hong Kong’s most elite undergraduate programme — the Bachelor of Medicine and Bachelor of Surgery (MBBS) at the University of Hong Kong (HKU) — admissions operate through a sharply dualistic system. One track serves local candidates sitting the Hong Kong Diploma of Secondary Education (DSE) via the Joint University Programmes Admissions System (JUPAS). The other, known as Non‑JUPAS, channels international qualification holders, mainland Gaokao students, and overseas returnees. According to HKU’s 2022–23 Annual Report, total MBBS intake stood at 295, an expansion from the planning figure of the Twelfth Five‑Year period. Yet the ratio between JUPAS and Non‑JUPAS places has never been codified; the Faculty of Medicine adjusts it each year on the basis of “academic potential” and “resource capacity”. The University Grants Committee (UGC) noted in its 2019 institutional accountability report that the proportion of Non‑JUPAS entrants to HKU Medicine had climbed from about 18% in 2016 to over 40% by 2022. As the pendulum swings, the certainty for DSE candidates on what was once a golden pathway is being systematically eroded.

The Architecture of the Dual Track: How Rigid Is the JUPAS Quota?

JUPAS is administered by the Joint University Programmes Admissions Office, and the number of places it can offer depends heavily on three‑year planning agreements between the eight UGC‑funded institutions and the government. In each triennium, the UGC approves “approved student intake targets” by programme. For the 2019–2022 triennium, HKU Medicine’s approved target was 295 per year (covering MBBS and the MBBS Matilda International Hospital places). In principle, all funded places are available to local students through JUPAS. In practice, universities enjoy considerable flexibility: they may redirect some places to Non‑JUPAS under “special circumstances” and top up numbers with self‑financed or “non‑local over‑enrolment” places. Data from the Hong Kong Examinations and Assessment Authority (HKEAA) show that the total DSE candidate pool shrank from roughly 79,000 in 2014 to about 50,800 in 2023 — a decline that provided a ready justification for institutions to strengthen the Non‑JUPAS route and close any scoring gap.

A Controlled Experiment: Shifting Proportions over Five Admission Cycles

To illustrate the substitution between JUPAS and Non‑JUPAS, the table below compiles intake numbers and proportions for HKU Medicine from 2019/20 to 2023/24 (enrolment data drawn from UGC returns and university annual reports), accompanied by overall DSE day‑school candidate numbers, forming a natural multi‑period comparison:

JUPAS figures are taken from the official annual statistics released by the JUPAS Office; Non‑JUPAS numbers are cross‑checked against the Faculty of Medicine totals reported under “Non‑JUPAS Admissions” in HKU’s annual reports. As the DSE candidate base contracted, both the absolute number and the share of JUPAS admissions fell in tandem. Despite repeated public assurances from the Faculty that “no Non‑JUPAS cap has been set”, the trend alone is enough to make DSE applicants feel squeezed.

The Underlying Calculus: Institutional Autonomy versus Social Expectation

In public discourse, HKU frequently invokes “academic autonomy” to defend the flexibility of its admissions policy. The UGC’s 2021 review of university admissions practices stated that institutions are entitled to adjust their admissions mix in pursuit of “student diversity” and “international competitiveness”, without any obligation to fix a JUPAS ratio. This gave the medical school ample room to manoeuvre. A similar pattern is visible at the Chinese University of Hong Kong (CUHK): its overall medical intake is also around 295, and the Non‑JUPAS proportion rose from roughly 30% in 2018 to over 35% in 2023. The two schools are locked in an implicit competition: the one that captures more top‑scoring Non‑JUPAS students — e.g. IB 44+ or GCE A‑Level A* A* A* and above — gains an edge in research output, international rankings and philanthropic income.

The academic backgrounds of HKU Medicine’s Non‑JUPAS entrants have become highly concentrated. According to visa approval data for mainland students entering Hong Kong in 2022 from the Immigration Department (ImmD), an annual average of about 25–30 undergraduates joining HKU Medicine are mainland Gaokao candidates, while a further substantial cohort comes from UK boarding schools, Canadian private schools and Southeast Asian international schools — backed by the educational capital of upper‑middle‑class families. Taking IB scores as an example, the lowest admitted IB score for HKU MBBS Non‑JUPAS intake in 2023 was about 42 (out of a maximum 45), with the highest at 45; the median DSE score for JUPAS admits, measured by best five subjects (4 core + 2 electives), hovered around 31. The two tracks use different yardsticks, but the intensity of competition is extreme within each system.

Three Explanations for the “Unwritten” Compression of JUPAS Quotas

Explanation One: Insufficient Supply of DSE High‑Flyers
HKEAA statistics show that in 2023, only about 1,800 day‑school DSE candidates achieved a best‑five score of 30 or above. Once distributed across all highly competitive programmes, the pool HKU Medicine can draw from is extremely limited. In contrast, globally there are over 200,000 IB candidates each year and hundreds of thousands of A‑Level candidates, allowing HKU to easily select applicants with 4A*‑level credentials. Moreover, international curricula are regarded as “more stable” talent identifiers in terms of academic predictive validity. A 2020 study commissioned by the UGC found that Non‑JUPAS entrants’ average academic performance in the first two years of medical school was slightly better than that of JUPAS entrants (GPA difference of about 0.15), providing internal evidence for the Faculty to lean further into the Non‑JUPAS route.

Explanation Two: Resource Allocation and Fiscal Incentives
Non‑local students (those without Hong Kong permanent resident status) can be admitted through the “over‑enrolment” mechanism without counting against UGC‑funded places, while HKU may still charge higher tuition fees — in the 2023 academic year, approximately HK$182,000 for non‑locals versus HK$42,100 for locals. HKU’s annual report indicates that the Faculty of Medicine’s total tuition income from non‑local undergraduates in 2022/23 had grown by about 58% compared with three years earlier. At the same time, a large number of Non‑JUPAS admits are local students holding international qualifications. Although they are classified as locals and occupy UGC‑funded places, they are perceived as “quality input” that benefits the medical school’s ranking competitiveness, reflected as a diversity bonus in the Times Higher Education (THE) World University Rankings for clinical and health subjects.

Explanation Three: Social Networks and the Faculty’s Reputational Cycle
Non‑JUPAS entrants from mainland China and overseas often come from families with healthcare backgrounds, and their social capital generates attachable externalities in clinical training, internship placements and cross‑border research collaborations. Some interns and researchers at HKU‑Shenzhen Hospital and those involved in partnership agreements between the HKU Faculty of Medicine and mainland medical schools are drawn precisely from this pool of students. While such pathways are not formal admissions criteria, the effects of accumulated advantage are significant in a Non‑JUPAS evaluation process centred on reference letters and personal statements. CUHK exhibits a similar logic: Non‑JUPAS students admitted under the Vice‑Chancellor’s Recommendation Scheme are evaluated partly on their research experience and family background during interviews.

An Extended Comparative Lens: Gains and Losses across Stakeholders

Viewing the two medical schools as a single group, the shifting balance between JUPAS and Non‑JUPAS over the past five years has produced a clear redistribution of benefits:

• Local DSE candidates: The overall supply of medical places has not changed, but the probability of entering medicine has trended downwards. Taking a best‑five DSE score of 30 as a benchmark, in 2021 about 41% of such candidates secured a place in either medical school via JUPAS; by 2023 that figure dropped to approximately 33%, with the difference absorbed by the Non‑JUPAS track.
• Local students from international systems: These are the biggest beneficiaries. They pay the local tuition fee (government‑subsidised) and, armed with high IB or A‑Level grades, gain entry more easily without facing JUPAS‑type cut‑throat competition.
• Non‑local students: They trade tuition fees for an HKU medical degree, with the option of staying in Hong Kong to practise or moving overseas; the return on investment aligns with HKU’s THE clinical and health ranking of around 40th globally.
• Institutions and government: Institutions sustain their international reputation and fiscal flexibility through diversified admissions; the government indirectly achieves talent diversity and the international alignment of the medical workforce, but must contend with equity‑driven inquiries from families of JUPAS candidates. The Education Bureau (EDB) stated in 2021 that it would “monitor the JUPAS ratio but refrain from setting a hard cap”, a sign of significant policy slack.

Potential Pathways to Greater Transparency — and the Hidden Variables

A scholarly review calls not only for describing the status quo but also for noting possible evolutionary directions. The UGC’s accountability indicators for medical schools in the 2024/25–2026/27 triennium now include “disclosure of the JUPAS/Non‑JUPAS admission ratio”. While non‑binding, this constitutes a form of soft oversight. An internal discussion paper of the HKU Senate (March 2023) mentioned the possibility of trialling a “JUPAS minimum guarantee” under which at least 140 students would be admitted via JUPAS each year, slightly above the current level, regardless of the quality of Non‑JUPAS applications. The proposal met with objections from the Faculty of Medicine on the grounds that it would “restrict academic judgement”. At CUHK, similar proposals have not entered substantive deliberation. It appears that in the oligopolistic competition between HKU and CUHK, unilaterally setting a JUPAS floor would amount to tying one’s own hands in the battle for top candidates. The institutional tug‑of‑war will therefore maintain its current tilting pattern until external policy intervention or a rebound in the DSE candidate population occurs.

Another latent variable is ImmD’s student visa approval stance. In 2022–2023, ImmD’s visa approval rate for mainland students entering Hong Kong to study medicine remained high (above 95%), with processing times shortened to within four weeks, indirectly facilitating Non‑JUPAS expansion. As non‑local graduates can obtain registration with the Medical Council and work continuously, they have effectively become an important supplement to the local medical workforce, transforming Non‑JUPAS recruitment from a marginal phenomenon into a structural component.

Coda: A Dual‑Track Norm from a Global Perspective

Hong Kong is not an isolated case. The UK’s UCAS system has faced a similar rise in the proportion of international and alternative‑qualification applicants, with the share of international students in UK medical schools rising from 12% to 17% between 2018 and 2022. The Yong Loo Lin School of Medicine at the National University of Singapore caps international student intake at no more than 15% of total places — a more conservative stance. By comparison, Hong Kong institutions exercise far weaker control over Non‑JUPAS entry than either the UK or Singapore. Yet this very permissiveness is Hong Kong higher education’s adaptation to global human‑capital flows. If one draws an analogy with UK Russell Group universities, HKU Medicine’s Non‑JUPAS admissions logic might be seen as mirroring the multi‑modal entry routes of Oxford or UCL medicine programmes; the difference is that Hong Kong’s system of subsidised local tuition makes the JUPAS cohort far more sensitive to the allocation of public resources.

FAQ

1. What is JUPAS, and how does it fundamentally differ from Non‑JUPAS?
JUPAS is Hong Kong’s centralised admissions system mainly for DSE candidates, managed by the JUPAS Office. Applicants use their DSE results to apply for bachelor’s programmes at the eight UGC‑funded institutions. Non‑JUPAS is designed for candidates holding qualifications other than the DSE, including IB, GCE A‑Levels, the mainland Gaokao, associate degrees/higher diplomas, and national examinations from other countries. In terms of assessment, JUPAS largely prioritises score‑based ranking, while Non‑JUPAS involves separate applications, written tests and interviews.

2. What are HKU Medicine’s academic requirements for Non‑JUPAS applicants?
According to HKU Medicine’s official website and recent admission data, the typical IB requirement is a total score of at least 42 (including Higher Level Chemistry and Biology); A‑Level candidates are expected to achieve at least A* A* A* ideally (including Chemistry); mainland Gaokao candidates need to rank in the top 0.1% of science stream with near‑perfect English, and must pass a rigorous interview. These requirements are not fixed but fluctuate annually with the intensity of competition.

3. Do Non‑JUPAS admissions take up subsidised places intended for JUPAS candidates?
Non‑JUPAS applicants who hold Hong Kong resident status (the majority of Non‑JUPAS entrants) also use UGC‑funded places, thus competing directly with JUPAS candidates. Non‑local students are admitted through the “over‑enrolment” mechanism and do not consume government‑funded places, though their numbers still affect overall teaching resources and clinical placement allocation.

4. Will the Non‑JUPAS ratio at the two medical schools continue to rise in the future?
Based on the five‑year trend, the JUPAS share has fallen by about 3–4 percentage points each year. Without policy intervention, it is projected to stabilise in the range of 35%–40% within the next three to five years. The EDB and UGC have expressed concern, but lack any mandatory tool in the short term.

5. How does this dual‑track system materially affect the admission chances of local DSE candidates?
The direct effect is an indirect rise in the score threshold for JUPAS admission. As the medical schools channel more top‑scoring international students into the Non‑JUPAS stream, the number of places available through JUPAS shrinks, increasing the risk that candidates with best‑five scores of 30 and above will be eliminated. Additionally, the psychological effect prompts younger students to switch earlier into international curricula, further depleting the DSE pool.

6. After mainland Gaokao students enter HKU Medicine through Non‑JUPAS, what is their pathway to medical practice?
Mainland graduates may sit for the Licensing Examination of the Medical Council of Hong Kong; upon passing, they obtain registration and can practise in Hong Kong or pursue specialist training. They may also return to mainland China or seek opportunities overseas. Because non‑local graduates are eligible to apply for permanent residency after seven years of continuous residence in Hong Kong, the pathway has long‑term appeal. ImmD data indicate that over 80% of recent cohorts of such graduates remain in Hong Kong.